Table 4.
Characteristics of the patients with Chronic Chikungunya arthritis (n = 60)
| Characteristics | All (n = 60) | Preexisting rheumatic disorders | Gender | ||
|---|---|---|---|---|---|
| Absent (n = 52) | Present (n = 8) | Male (n = 26) | Female (n = 34) | ||
| Age (in years) | |||||
| Up to 40 | 27 (45.0) | 23 (44.2) | 4 (50.0) | 14 (53.8) | 13 (38.2) |
| > 40 | 33 (55.0) | 29 (55.8) | 4 (50.0) | 12 (46.2) | 21 (61.8) |
| Women | 34 (56.7) | 27 (51.9) | 7 (87.5) | ||
| Comorbidity | 30 (50.0) | 24 (46.1) | 6 (75.0) | 9 (34.6) | 21 (61.8) |
| No preexisting rheumatic disorders | 52 (86.7) | 25 (96.1) | 27 (79.4) | ||
| IgG positive | 19 (31.7) | 16 (30.8) | 3 (37.5) | 6 (23.1) | 13 (38.2) |
| Type of joint involvement | |||||
| Only pain | 39 (65.0) | 34 (65.4) | 5 (62.5) | 18 (69.2) | 21 (61.8) |
| Pain with swelling | 21 (35.0) | 18 (34.6) | 3 (37.5) | 8 (30.8) | 13 (38.2) |
| Laboratory finding | |||||
| Anti CCP | 1(1.7) | 0 (0.0) | 1 (1.9) | 1 (3.8) | 0 (0.0) |
| HLA B27 | 2 (3.4) | 1 (1.9) | 1 (1.9) | 1 (3.8) | 1 (2.9) |
| Anti CCP + HLA B27 | 1 (1.7) | 1 (1.9) | 0 (0.0) | 1 (3.8) | 0 (0.0) |
| RF | 2 (3.3) | 1 (1.9) | 1 (1.9) | 1 (3.8) | 1 (2.9) |
| Ultra-sonographic findings | |||||
| Tenosynovitis | 19 (31.7) | 19 (36.5) | 0 (0.0) | 9 (34.6) | 10 (29.4) |
| Synovial hypertrophy | 8 (13.3) | 8 (15.4) | 0 (0.0) | 2 (7.7) | 6 (17.6) |
| Tendinitis | 7 (11.7) | 6 (11.5) | 1 (1.9) | 5 (19.2) | 2 (5.9) |
| Median nerve entrapment | 4 (6.7) | 4 (7.7) | 0 (0.0) | 1 (3.8) | 3 (8.8) |
| Joint effusion | 3 (5.0) | 2 (3.8) | 1 (1.9) | 1 (3.8) | 2 (5.9) |
| Bursitis | 2 (3.3) | 2 (3.8) | 0 (0.0) | 1 (3.8) | 1 (2.9) |
| X-ray finding | |||||
| Unilateral sacroiliitis | 1 (1.7) | 0 (0.0) | 1 (1.9) | 0 (0.0) | 1 (2.9) |
| Bilateral sacroiliitis | 4 (6.7) | 4 (7.7) | 0 (0.0) | 1 (3.8) | 3 (8.8) |
| Functional disability at one year | (n = 21) | (n = 17) | (n = 4) | (n = 9) | (n = 12) |
| Mild | 18 (85.7) | 15 (28.8) | 3 (37.5) | 8 (30.8) | 10 (29.4) |
| Moderate | 2 (3.3) | 2 (3.8) | 0 (0.0) | 1 (3.8) | 1 (2.9) |
| Severe | 1 (1.7) | 0 (0.0) | 1 (1.9) | 0 (0.0) | 1 (2.9) |
Numbers in parentheses indicated percentages. CCP Cyclic citrullinated peptide, HLA-B27 Human leukocyte antigen B27, RF Rheumatoid Factor